Thomas Adam Wichelmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Thomas Adam Wichelmann has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Eli Daniel Ehrenpreis
Advocate Lutheran General Hospital
2 shared publications - Abdullah Malas
Oncology, Advocate Lutheran General Hospital, Park Ridge, USA
1 shared publication - Dean N. Silas
Division of Gastroenterology, Department of Medicine, Advocate Lutheran General Hospital, Park Ridge, Illinois, USA
1 shared publication - Edward James
Oncology, Advocate Lutheran General Hospital, Park Ridge, USA
1 shared publication Hardeep S. Ahdi
Resident, Department of Internal Medicine, Advocate Lutheran General Hospital, Park Ridge, IL
1 shared publication- Komal Patel
Internal Medicine, Advocate Lutheran General Hospital, Park Ridge, USA
1 shared publication
Latest Publications
- Open Access
- 30 December 2021
- Published by S. Karger AG in Case Reports in Gastroenterology
- Vol. 15 (3) , 1003-1007
Acute Herpes Simplex Esophagitis in an Immunocompetent Adult with Eosinophilic Esophagitis
Herpes simplex esophagitis (HSE) represents a rare entity in immunocompetent patients and has infrequently been described in association with eosinophilic esophagitis (EoE). Causality in this rare association remains a debated topic. We present a case of HSE occurring in an immunocompetent adult with EoE and review the literature in support of EoE induced mucosal disruption predisposing to increased risk of HSE.
- 30 December 2021
- Published by S. Karger AG in Case Reports in Gastroenterology
- Vol. 15 (3) , 1003-1007
Open AccessAcute Herpes Simplex Esophagitis in an Immunocompetent Adult with Eosinophilic Esophagitis
Herpes simplex esophagitis (HSE) represents a rare entity in immunocompetent patients and has infrequently been described in association with eosinophilic esophagitis (EoE). Causality in this rare association remains a debated topic. We present a case of HSE occurring in an immunocompetent adult with EoE and review the literature in support of EoE induced mucosal disruption predisposing to increased risk of HSE.
- 9 September 2021
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 54 (10) , 1290-1297
Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database
Summary: Background: Bevacizumab is used in the treatment of advanced malignancies and has a “black box” warning for gastrointestinal perforations. Despite this known side effect, there are no large descriptive series of patients who experience bevacizumab‐induced gastrointestinal perforations.Aim: To review and describe post‐market cases of bevacizumab‐induced gastrointestinal perforation reported by healthcare professionals to the United States Food and Drug Association Adverse Event Reporting System (FAERS) database.Methods: In total, 74 025 cases of bevacizumab‐induced adverse drug reaction were reported to FAERS from January 1 2004 to July 6 2021. We identified 2874 cases of bevacizumab‐induced gastrointestinal perforation. A total of 1375 cases were determined to contain complete patient demographic data after the removal of duplicates and were reviewed. Subgroup analysis was completed on gastro‐oesophageal perforations given the lack of prior data.Results: The average patient age was 61.9 ± 11.4 years. A total of 698 cases included descriptive locations of perforations with most occurring in the large intestine (385 cases, 55.2% of specifically described cases). Colorectal cancer was the most common indication for bevacizumab (691 cases, 50.3%) followed by ovarian cancer (197 cases, 14.3%) and non‐small cell lung cancer (182 cases, 13.2%). Death was reported in 554 patients (40.3% of cases). Sixty‐two cases of gastro‐oesophageal perforation were identified.Conclusions: This is the largest collective descriptive study of bevacizumab‐induced gastrointestinal perforations, and sheds light on this often fatal complication. We additionally identified and described a rare subgroup of patients experiencing bevacizumab‐induced gastro‐oesophageal perforation not previously described.
- 9 September 2021
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 54 (10) , 1290-1297
Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database
Summary: Background: Bevacizumab is used in the treatment of advanced malignancies and has a “black box” warning for gastrointestinal perforations. Despite this known side effect, there are no large descriptive series of patients who experience bevacizumab‐induced gastrointestinal perforations.Aim: To review and describe post‐market cases of bevacizumab‐induced gastrointestinal perforation reported by healthcare professionals to the United States Food and Drug Association Adverse Event Reporting System (FAERS) database.Methods: In total, 74 025 cases of bevacizumab‐induced adverse drug reaction were reported to FAERS from January 1 2004 to July 6 2021. We identified 2874 cases of bevacizumab‐induced gastrointestinal perforation. A total of 1375 cases were determined to contain complete patient demographic data after the removal of duplicates and were reviewed. Subgroup analysis was completed on gastro‐oesophageal perforations given the lack of prior data.Results: The average patient age was 61.9 ± 11.4 years. A total of 698 cases included descriptive locations of perforations with most occurring in the large intestine (385 cases, 55.2% of specifically described cases). Colorectal cancer was the most common indication for bevacizumab (691 cases, 50.3%) followed by ovarian cancer (197 cases, 14.3%) and non‐small cell lung cancer (182 cases, 13.2%). Death was reported in 554 patients (40.3% of cases). Sixty‐two cases of gastro‐oesophageal perforation were identified.Conclusions: This is the largest collective descriptive study of bevacizumab‐induced gastrointestinal perforations, and sheds light on this often fatal complication. We additionally identified and described a rare subgroup of patients experiencing bevacizumab‐induced gastro‐oesophageal perforation not previously described.
- Open Access
- 4 December 2020
- Published by Springer Nature in Cureus
- Vol. 12 (12)
A Unique Case of Alpha-Fetoprotein-Negative Hepatoid Adenocarcinoma of the Stomach With Associated Signet Ring Cell Histological Features and Linitis Plastica
Hepatoid adenocarcinoma of the stomach (HAS), a rare and unique histological subtype of gastric cancer, accounts for less than 1.5% of all gastric cancers. Historically, this subtype is found to have a poor prognosis in comparison to other types of gastric cancer. While the diagnosis is made based on pathological findings, most cases described in the literature are associated with elevated alpha-fetoprotein (AFP) levels. We present a case of AFP-negative HAS with additional unique pathologic findings of signet ring cells which has been reported only once in the literature. Given the rare and late presentation of the disease, AFP-negative HAS should be included in the differential diagnosis in patients with suspicion for gastric cancer.
- 4 December 2020
- Published by Springer Nature in Cureus
- Vol. 12 (12)
Open AccessA Unique Case of Alpha-Fetoprotein-Negative Hepatoid Adenocarcinoma of the Stomach With Associated Signet Ring Cell Histological Features and Linitis Plastica
Hepatoid adenocarcinoma of the stomach (HAS), a rare and unique histological subtype of gastric cancer, accounts for less than 1.5% of all gastric cancers. Historically, this subtype is found to have a poor prognosis in comparison to other types of gastric cancer. While the diagnosis is made based on pathological findings, most cases described in the literature are associated with elevated alpha-fetoprotein (AFP) levels. We present a case of AFP-negative HAS with additional unique pathologic findings of signet ring cells which has been reported only once in the literature. Given the rare and late presentation of the disease, AFP-negative HAS should be included in the differential diagnosis in patients with suspicion for gastric cancer.